Search results
Results from the WOW.Com Content Network
In a phase III clinical trial, it was found to be effective for resolving noncirrhotic nonalcoholic steatohepatitis and improving liver fibrosis. [ 5 ] The US Food and Drug Administration (FDA) evaluated the safety and efficacy of resmetirom based on an analysis of a surrogate endpoint at month twelve in a 54-month, randomized, double-blind ...
2021 meta-analyses of trials over periods of 1 to 28 months found limited evidence to indicate that lifestyle modifications and nutritional supplementation have an effect on mortality, liver cirrhosis, liver decompensation, liver transplantation, and hepatocellular carcinoma in people with non-alcohol-related fatty liver disease; authors said ...
Thyromimetics selective for TRβ—including eprotirome, [3] sobetirome, [4] resmetirom, [5] and the prodrug VK2809—have been investigated for the treatment of non-alcoholic fatty liver disease, dyslipidemia, and other metabolic and neurodegenerative diseases. [3]
In clinical trials, Rezdiffra helped improve liver scarring or resolve NASH after 12 months. Weight loss injections like semaglutide have also been found to directly improve fatty liver disease.
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
Mattson adds that randomized controlled trials so far have been focused on adult women and men - studies that "have not revealed any harms of intermittent fasting" in those groups. But "there have ...
The drug has a black box warning about the risk of liver damage; specifically it can cause elevations in the levels of transaminases and causes fatty liver disease. [1]In clinical trials, 18% of subjects taking mipomersen stopped using the drug due to adverse effects; the most common adverse effects leading to discontinuation were injection site reactions, increases of transaminases, flu-like ...
The results of that randomized clinical trial, conducted at 84 sites in the United States from September 2019 to May 2024, are now presented in two studies published Wednesday in the journal Brain ...